# CXCL1: a novel therapeutic target to increase aneurysm healing after coil embolization

**Authors:** Devan Patel, Melanie Martinez, Supreeya A. Saengchote, Kartik Motwani, William S. Dodd, Zahra Hasanpour Segherlou, Haiyan Xu, Koji Hosaka, Brian L. Hoh

PMC · DOI: 10.3389/fstro.2026.1746652 · Frontiers in Stroke · 2026-02-10

## TL;DR

Blocking CXCL1 improves healing of brain aneurysms in mice by reducing inflammation and promoting tissue repair.

## Contribution

CXCL1 neutralization is shown to enhance aneurysm healing after coil embolization in mice.

## Key findings

- CXCL1 neutralization for 14 or 21 days significantly increased aneurysm healing in both female and male mice.
- 14 days of CXCL1 neutralization reduced neutrophil infiltration and increased reparative M2 macrophages.
- CXCL1 neutralization is a promising therapy to modulate inflammation and improve aneurysm healing.

## Abstract

CXCL1 is highly expressed in human aneurysms but its role in aneurysm healing is unknown. The objective of this study was to determine whether CXCL1 neutralization increases murine aneurysm healing post-coiling.

Carotid artery aneurysms were created in female and male C57BL/6 mice. CXCL1 expression was compared between aneurysms and sham-operated carotid arteries. In a separate cohort, aneurysms were coiled with poly (lactic-co-glycolic acid) (PLGA)-coated coils. Mice received intraperitoneal injections of either CXCL1 neutralizing antibody or IgG control for 7, 14, or 21 days post-coiling. Coiled aneurysms were assessed for aneurysm healing, neutrophil infiltration, macrophage polarization, and total macrophage burden.

CXCL1 is highly expressed in murine carotid artery aneurysms. CXCL1 neutralization significantly increased aneurysm healing compared to IgG when administered for 14 days (females: 66.4% vs. 51.2%, p = 0.03; males: 69.8% vs. 47.0%, p = 0.004) and 21 days (females: 71.9% vs. 44.3%, p = 0.002; males: 67.8% vs. 61.6%, p = 0.02), but not when given for only 7 days (females: 48.1% vs. 49.4%; males: 52.3% vs. 50.4%). 14 days of CXCL1 neutralization decreased neutrophil infiltration (females: 0.43 vs. 5.21 cells/high power field (hpf), p = 0.04; males: 0.00 vs. 4.42 cells/hpf, p = 0.04) and increased reparative M2 macrophages (females: 2.25 vs. 0.79 cells/hpf, p = 0.03; males: 2.00 vs. 0.27 cells/hpf, p = 0.02).

CXCL1 neutralization for 14 or 21 days improved aneurysm healing in female and male mice. 14 days of CXCL1 neutralization decreased neutrophil infiltration and increased M2 macrophage polarization. Systemic CXCL1 neutralization is a promising potential therapy to improve aneurysm healing by modulating the inflammatory response after coiling.

## Linked entities

- **Genes:** CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919]
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Cxcl1 (C-X-C motif chemokine ligand 1) [NCBI Gene 14825] {aka Fsp, Gro1, KC, Mgsa, N51, Scyb1}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}
- **Diseases:** Carotid artery aneurysms (MESH:D002340), thrombus (MESH:D013927), subarachnoid hemorrhage (MESH:D013345), IA (MESH:D002532), injury (MESH:D014947), inflammation (MESH:D007249), IAs (MESH:C535739), Aneurysm (MESH:D000783), IA) rupture (MESH:D017542), carotid aneurysms (MESH:D020212), WD (MESH:D006527)
- **Chemicals:** Alexa Fluor (-), hematoxylin (MESH:D006416), 2-methylbutane (MESH:C067038), sucrose (MESH:D013395), PFA (MESH:C003043), eosin (MESH:D004801), PLGA (MESH:D000077182), PBS (MESH:D007854), 4',6-diamidino-2-phenylindole (MESH:C007293), platinum (MESH:D010984), xylazine (MESH:D014991)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929126/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929126/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929126/full.md

---
Source: https://tomesphere.com/paper/PMC12929126